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Abstract: The incidence of cardiometabolic diseases, such as obesity, diabetes, and cardiovascular
diseases, is constantly rising. Successful lifestyle changes may limit their incidence, which is why
researchers focus on the role of nutrition in this context. The outcomes of studies carried out in past
decades have influenced dietary guidelines, which primarily recommend reducing saturated fat as
a therapeutic approach for cardiovascular disease prevention, while limiting the role of sugar due
to its harmful effects. On the other hand, a low-carbohydrate diet (LCD) as a method of treatment
remains controversial. A number of studies on the effect of LCDs on patients with type 2 diabetes
mellitus proved that it is a safe and effective method of dietary management. As for the risk of
cardiovascular diseases, the source of carbohydrates and fats corresponds with the mortality rate and
protective effect of plant-derived components. Additionally, some recent studies have focused on the
gut microbiota in relation to cardiometabolic diseases and diet as one of the leading factors affecting
microbiota composition. Unfortunately, there is still no precise answer to the question of which a
single nutrient plays the most important role in reducing cardiometabolic risk, and this review article
presents the current state of the knowledge in this field.
Keywords: carbohydrates; diabetes mellitus; diet; fat; microbiota
1. Introduction
The incidence of cardiometabolic diseases is increasing, with a worldwide epidemic
of obesity, diabetes, and atherosclerotic cardiovascular diseases. Since 1975, the preva-
lence of obesity has almost tripled and, in 2016, the number of obese patients exceeded
650 million [1]. In the United States, it has been predicted that, by 2030, almost one in two
adults will be obese, and the prevalence will be higher than 50% in most states and not
below 25% in any state [2]. This situation is similar for diabetes mellitus, where, in 2019,
the number of patients aged between 20 and 79 years was estimated to be 463 million
worldwide [3]. Obesity and diabetes are both strong risk factors for cardiovascular diseases.
It is estimated that more than 700,000 deaths per year in the United States alone are caused
by cardiometabolic diseases and approximately 50% of them are related to diet [4]. World
Health Organization (WHO) statistics state that, worldwide, 17 million people die of cardio-
vascular diseases (CVD) annually [5]. Diet type is one of the interventions, besides physical
activity, influencing cardiometabolic health. Since the beginning of the 20th century, there
has been an ongoing debate on which diet type is favorable in relation to cardiometabolic
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health, which is, whether this should be a low-fat diet (LFD) or a low-carbohydrate diet
(LCD). Recently, a third aspect to this debate has been introduced, namely the gut micro-
biota, which are involved in the cardiometabolic health of the host through diet type, which
complicates the present knowledge gap that is related to the influence of diet on metabolic
health [6].
Hence, there is still no precise answer to the question of which the type of nutrient
plays the most important role in the reduction in cardiometabolic risk and this review
article presents the current state of the knowledge in this field.
2. Epidemiological Insights
In the middle of the 20th century, coronary heart disease (CHD) was recognized as an
epidemic [7]. This started a series of studies on the causes of this disease. In 1908, when
a link was established between a high cholesterol intake and the faster development of
atherosclerosis in rabbits [8], it was realized that the CVD in humans could be related to
nutrition. A prophylactic change in diet, especially in combination with physical activity,
which would reduce the risk of developing CVD by even a small percentage, may signif-
icantly affect the number of people who will develop CVD and, thus, reduce the cost of
patients’ care [9].
In the mid-1950s, the first studies on the influence of the presence of fat in the diet
on the risk of developing CVD began [10]. In 1958, the Seven Countries Study (SCS) was
launched, the aim of which was to collect data and deepen the knowledge regarding
the variables that are likely to be relevant for the CHD epidemiology [11]. In the SCS,
16 culturally diverse cohorts (southern, central and northern Europe, Japan, Italy, and the
United States) were selected, representing a wide range of differences in dietary fat and
carbohydrate intake. Keys et al. noted that the differences between populations in the
incidence of CHD are related to lifestyle, especially the type of diet, particularly its fat
content [12]. The intake of large amounts of this macroelement resulted in an increase in
the total plasma cholesterol concentration, one of the first CVD risk factors identified.
High serum cholesterol concentration is correlated with a high risk of mortality from
CHD [13]. The recommendations for the reduction in saturated dietary fats to reduce
CVD risk appeared in the American Heart Association (AHA) guidelines as early as in
1961 [14]. In 1970, the preliminary results of the SCS were published, showing a lower
incidence of CVD in inhabitants of the Mediterranean coast, Greece, southern Italy, and
former Yugoslavia [15]. The diet from these regions was referred to as the Mediterranean
Diet (MED), and it differed from the American and North European diets, in that it
contained much less meat and dairy products and more fruit, vegetables, and whole grain
products [15–17]. The main sources of fat were olive oil and nuts [17]. This diet seemed to
be a factor determining the large difference in CVD prevalence between the populations of
the Mediterranean coast and Western cohorts in the SCS [15].
However, this hypothesis was not matched by epidemiological data that were collected
from the French population. It was observed that, despite the high level of saturated fat
intake, CVD-related mortality was low [18,19]. This phenomenon was called the French
Paradox. Studies have shown that the consumption of wine and its phenolic compounds
in moderate quantities, as in the French culture, can have a cardioprotective effect [20].
A direct effect on the development of atherosclerosis causes this, increasing the level of
high-density lipoprotein cholesterol (HDL-C), as well as by the hemostatic mechanism,
which prevents platelet aggregation [19,21]. It is now known that the phenolic compounds
that are derived from wine will also reduce low-density lipoprotein cholesterol (LDL-C)
oxidation, oxidative stress, cause an increase in NO (nitrogen oxide) release, and, in this
way, improve the endothelial function [22,23]. The effects of these compounds may cause
the so-called French Paradox.
At the end of the 1950s, a debate emerged as to whether fat or sugar would be a worse
diet macronutrient in relation to heart diseases [24]. Keys (via the SCS) claimed that dietary
fat was to blame for the increasing number of heart diseases [25]. Meanwhile, a British
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nutritionist, John Yudkin, blamed carbohydrates—primarily refined sugars—given that
sugar consumption rose in parallel with the increase in heart diseases when people broadly
consumed meals that were low in fat [26,27].
For decades, starting from 1980, dietary guidelines recommended lowering the to-
tal fat and saturated fatty acids (SFA) [28], and these were updated in 1990 in order to
recommend LFDs, specifically consisting of ≤30% of total fat and ≤10% SFA of the total
daily energy [29]. At the same time, as fat decreased in the American diet [30], there was a
rise in the consumption of refined grains [31] and an increase in the prevalence of type 2
diabetes mellitus (T2DM) and CVD [32,33]. Because obesity is a well-recognized risk factor
for T2DM, there has been increasing interest in LCD for weight loss, especially since the
1970s, when “Dr. Atkins’ New Diet Revolution” became a worldwide phenomenon [34]. In
fact, the history of LCD began in 1797, when John Rollo described two cases of soldiers
with T2DM that was treated with carbohydrate restriction [35,36] and, later on, in 1869,
when William Banting, in his open letter, proposed LCD as a successful method to lose
weight. Banting himself lost 46 pounds (approximately 21 kg), when his acquaintance,
Claude Bernard, prescribed him an LCD regime [37,38]. Over the years, LCD has had
supporters and opponents. This diet permanently became the subject of research into
dietary approaches not only due to its ability to reduce body weight, but also because of
its role in the prevention and treatment of many diseases. LCD remains controversial, but
there has recently been increased interest in this type of diet [34,39–44]. In fact, the exact
amount of carbohydrate to be eaten daily for optimal health is unknown [45], although the
recommended daily carbohydrate intake is approximately 45% of total calorie intake [46].
According to Feinman et al., the definition of LCD is consuming less than 130 g of carbohy-
drates per day and less than 26% of energy from carbohydrates [47]. Currently, the WHO
and other worldwide authorities emphasize how important the type of carbohydrates
consumed is: the preferred ones are unrefined carbohydrates rich in fiber, vitamins, and
minerals with simple sugars being limited to a maximum of 10% of total calories per
day [48]. An extreme type of LCD is a very low-carbohydrate diet (VLCD), which contains
less than 20 to 50 g of carbohydrates and below 10% of energy from carbohydrates [47]. A
special type of this kind of diet is the ketogenic diet, which combines a very low carbohy-
drate, high fat, and moderate protein consumption [49]. In 2019, The American College
of Cardiology (ACC)/AHA guidelines on the primary prevention of CVD introduced
guidance on diet counseling [50]. Within these guidelines, there was emphasis placed on
a whole foods approach, rather than focusing on a single nutrient, encouraging a higher
intake of fresh vegetables and fruits and limiting the consumption of processed meats and
sugary beverages to reduce the atherosclerotic cardiovascular disease (ASCVD) risk [50].
More recent years have highlighted another link to diet and cardiometabolic disease,
the gut microbiota, which are involved in the metabolic control of the host [51]. Dysbiotic
gut microbiota are thought to be related to cardiometabolic diseases, such as obesity [52],
T2DM [53], and CVD [54–56], which is why gut modulation strategies, like diet intervention,
may provide some possibility for reducing cardiometabolic risk through correcting the
microbial gut imbalance. Figure 1 summarizes the timelines related to fat, sugar, and
microbiota studies.
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3. Low-Fat Diet and Obesity
The general fact is that it is impossible to lose weight without a negative energy
balance [57] and, in addition to the daily energy reduction, macronutrient composition
has been an important is ue that is examined in various studies for many years. LFDs
for weight l ss wer recomm nded e t the convic ion hat energy from fat is less
satiati g when compared to carbohydrates [58], as carbohydrate is more thermogenic than
fat and [59] high fat intake may cause intesti al dysbiosis with a detrimental impact on
metabolic variabl 60 .
D ta from a me a- nal is of tudies assessing LFDs and LCDs’ influence on weight
loss, when comparing results from 48 randomized trials (total 7286 participants, median age
of 45.7 years, median BMI of 33.7), showed that both LFD and LCD re associated with
similar body weight loss i 12 months, and the differences between them were minimal
(LCD—7.25 kg (95% CI, 5.33 to 9.25 kg) and LFD—7.27 kg (95% CI, 5.26 to 9.34 kg) [61]. LCD
and LFD both reduced body weight by 8 kg on average in a 6-month observation compared
to no diet. Approximately 1 to 2 kg of this effect was lost during the 12-month observation.
This confirms the thesis that most calorie-lowering diets lead to clinically significant weight
loss as long as the diet is aintained. Indeed, it is important to choose a diet that will be
best tolerated by the patient, as the time spent following the diet is more important than
the content of individual macronutrients [61]. Similarly, the Diet Intervention Examining
The Factors Interacting with Treatment Success (DIETFITS) trial, assessing the effect of
LFDs vs. LCDs on 12-month weight loss, also revealed that there is no significant difference
in the weight loss between those two types of diets [62]. Meckling et al. observed the
same outcome [63] The results are largely in line with the recommendations that were
published by the Joint Guidelines from the AHA, ACC, and the Obesity Society [64], which
stress the importance of following healthy eating patterns, which could be DASH (Dietary
Approaches to Stop Hypertension) diet or the Healthy Mediterranean-Style Eating Pattern,
instead of simply identifying that one diet is superior to the others. However, studies
assessing LFD and LCD are still performed, and Chawla et al. recently proved, in their
meta-analysis, that LFD had a lesser effect on weight loss when compared to LCD [65].
Table 1 summarizes the trials focusing on LFD in obesity.
Nutrients 2021, 13, 639 5 of 24




Average Duration of Follow-Up Population Diet Type Compared
Findings
(Weight Loss/Hunger)




Overweight and obese adult men
and women LFD vs. LCD
No significant differences in body weight
between the studied groups of patients




6 and 12 months
Overweight and obese
(BMI ≥ 25 kg/m2) adults without
co-morbidities.
LCD vs. LFD vs. no special diet
Weight loss observed on LCD was: 8.73 kg
(95% CI: 7.27 to 10.20 kg) after 6 months of
follow-up and 7.25 kg (95% CI: 5.33 to
9.25 kg) after 12 months.
Weight loss on LFD was 7.99 kg (95% CI,
6.01 to 9.92 kg) after 6 months of follow-up
and 7.27 kg (95% CI, 5.26 to 9.34 kg) after
12 months. There were no significant
differences between diets.




Adults without diabetes with a BMI
28–40 LFD vs. LCD
There was no significant difference in
weight loss.




6 and 12 months
Healthy adult,
BMI 22 and 43.6 kg/m2 LCD vs. LFD
LCD at 6–12 months was favored for
average weight change—polled
analyses—mean difference −1.30 kg;
95% CI −2.02 to −0.57
Abbreviations: BMI—Body Mass Index; T2DM—type 2 diabetes mellitus; LCD—low-carbohydrate diet; LFD—low-fat diet. RCT-randomized controlled trial; DIETFITS - Diet Intervention Examining The Factors
Interacting with Treatment Success.
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4. Low-Fat Diet in Type 2 Diabetes Mellitus
An acceptable consumption of total fat for all adults is said to be 20–35% of total
daily calorie intake [45]. There is a need to look at the type and quality of fat rather than
quantity, because it may influence CVD [66–68] and synthetic sources of trans fats need to
be avoided [28,69,70]. Additionally, a systematic review and meta-analysis indicate that
lowering the total fat intake does not necessarily improve glycaemia and CVD risk [71–73],
and the positives from LFD are mostly related to weight loss [69,74]. Lately, the evidence
seems to indicate that the major aspect for CVD prevention is the quality of fat consumed,
rather than the total amount of fat intake [66]. In relation to the quality of fat, it is important
to look at MUFA (monounsaturated fatty acids), PUFA (polyunsaturated fatty acids), and
SFA (saturated fatty acids) [75]. Although their division into three major groups is helpful
in determining structural affiliation, it may lead to oversimplified conclusions regarding the
effect of fat type on cardiovascular risk [76]. PUFAs can be divided into n-6 and n-3 PUFAs,
derived from linoleic acid (LA) and a-linolenic acid (ALA). These acids are not synthesized
in the human body; therefore, they must be consumed [75]. Replacing SFAs with PUFAs
has so far shown the best effect on lipid profile, but the research results vary, depending on
which lipids are studied [75,76]. In addition to its inhibitory effect on atherosclerosis, MUFA
may also have a role in lowering blood glucose concentration, which could be important
for patients with diabetes [70,76]. LFD appears to have a significantly smaller effect on
T2DM control than LCD [77,78], but, as was proved in other studies, the differences in the
results are statistically insignificant [79–81]. Table 2 summarizes the studies assessing LFD
and high-quality fat in patients with T2DM.
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Brunerova et al. (2007) [70]
RCT
1/58
3 months T2DM and obese non-T2DM adults
High-fat diet enriched with MUFA vs.
conventional diet
Decrease in HbA1c
from 7.3 ± 0.4% to 6.6 ± 0.3% (p < 0.01) on high-fat diet enriched
with MUFA
vs. from 6.9 ± 0.6% to 6.5 ± 0.5% (p > 0.01) on conventional diet
Davis et al. (2009) [79]
RTC
1/105
1 year Overweight adults with T2DM LCD vs. LFD There was no significant change in HbA1C in either group.
Brehm et al. (2009) [74]
Cohort study
1/1124
1 year Overweight and obese T2DM adults High-quality high-MUFA diet vs. HCD
Both diets were equally effective; no significant differences
were shown
Iqbal et al. (2010) [80]
RTC
1/144
2 years Obese adults with T2DM LCD vs. LFD
At month 6, LCD was associated with a clinically significant
reduction in HbA1c of −0.5% (compared to −0.1% on LFD), but
this was not sustained over time





with TDM2. MED vs. no diet
HbA1c decreased from 7.1% (95% CI: 6.5–7.7) to 6.8% (95% CI:
6.3–7.3) (p = 0.012) on MED diet




2 years Adults with TDM2 LFD vs. LCD
HbA1c LCD at 6 months −4.8 ± 8.3 mmol/mol, p = 0.004, at
12 months −2.2 ± 7.7 mmol/mol, p = 0.12; LFD at 6 months
−0.9 ± 8.8 mmol/mol, p = 0.56)
Insulin doses were reduced in the LCD group (0 months,
LCD 42 ± 65 E, LFD 39 ± 51 E; 6 months, LCD 30 ± 47 E,
LFD 38 ± 48 E; p = 0.046 for between-group change)





free of cardiovascular disease but with
T2DM; the participants followed oral
anti-diabetic treatments.
Participants of the PREDIMED
MED with olive oil vs. MED with nuts vs.
LFD
The adiponectin/HOMA-IR (A/HOMA-IR) ratio was
significantly increased in the MED with olive oil eatery group
and the trend was observed in the MED with nut eatery group
(p = 0.069) and the LFD group (p = 0.061).




Up to 3 years Adults with T2DM High-MUFA diet vs. HCD
Reductions in fasting plasma glucose: WMD−0,57 mmol/l
[95%CI−0.76,−0.39] on High-MUFA diet compared to HCD




3–48 months Adults with T2DM LCD vs. LFD
LCD caused significantly greater reduction in HbA1c than LFD:
(95% CI) −0.35 (−0.56/−0.14)%




3 months Chinese T2DM adults LCD vs. LFD
LCD caused significantly greater reduction in HbA1c than LFD:
(95% CI) −0.63% vs. −0.31%, p < 0.05.
Abbreviations: BMI—Body Mass Index; FPG—fasting plasma glucose, HbA1c—Glycated hemoglobin; HCD—high-carbohydrate diet; HOMA-IR—Homeostatic Model Assessment for Insulin Resistance;
LCD—low-carbohydrate diet; MUFA—monounsaturated fatty acids; MED—Mediterranean diet; PUFA—polyunsaturated fatty acids; T2DM—type 2 diabetes mellitus; RCT—randomized controlled trial.
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5. Low-Fat Diet and Cardiovascular Risk
The caloric demand is covered by three main macronutrients: fats, carbohydrates, and
proteins. A reduction in the intake of one component leads to an increase in the intake of
another to maintain the energy balance.
The impact of reduced saturated fat intake on the development of CVD is highly
dependent on the ingredients that replace it [20,82–85]. In the studies where energy from
saturated fats was mostly replaced by carbohydrates, there was no significant reduction in
the CVD incidence observed [9,86,87]. Favorable correlations occurred where saturated fats
were replaced by unsaturated fats, especially PUFA, which suggests that the final results
of the study may have been influenced by an increased consumption of polyunsaturated
fats [88,89].
The most predictive measure for CHD is not total plasma cholesterol concentration,
but the ratio of total cholesterol to HDL-C [90]. Saturated fats increase the concentration of
both HDL-C and LDL-C, which has minimal effect on the ratio of total cholesterol to HDL-C.
However, there is evidence that the replacement of saturated fats by PUFA, such as omega-3
ALA or docosahexaenoic acid (DHA), leads to a reduction in atherosclerosis development
and, thus, CHD [91–93]. PUFAs mainly act by improving the lipid profile by lowering
total cholesterol levels, triglycerides and LDL-C. Moreover, they have a positive effect on
atherosclerotic plaque stability, platelet aggregation, concentration of proinflammatory
cytokines, and immune cells [94]. Furthermore, omega-3 PUFAs have a beneficial effect on
endothelial progenitor cell biology [95]. Omega-3 fatty acid supplementation is currently
used to reduce the risk of cardiovascular events [94]. In the treatment and prophylaxis of
CVD, the most important direction is the introduction of a healthy, balanced diet, while
taking the controlled content of fatty acid into account [92].
Since the pioneering SCS, many randomized clinical trials (RCT) and meta-analyses of
observational and RCT studies have been conducted. The results have led to heterogeneous
conclusions regarding the relationship between saturated fat intake and CVD development
risk [89,96–99].
The largest intervention study PREDIMED (Prevención con Dieta Mediterránea), on
the use of the MED, showed that, among the participants (patients without CVD at the
beginning of the study, but with a high risk of developing these conditions), a lower
incidence of cardiovascular events during the five-year observation period was noticed
in people who were on a diet with olive oil or nuts than in people on LFD [100]. In 2017,
concerns were raised regarding the PREDIMED study, especially irregularities in the
randomization procedures; therefore, in June 2018, the basic report was retracted [100] and
republished [101] in a corrected form, which took any deviations in the conduct of the
study into account, although the conclusions remained the same. Table 3 summarizes the
associations between low-fat and high-quality fat diets and cardiovascular risk.
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CVD Mortality CHD Risk Lipids/BloodPressure AF














There was no direct
association between reduced
saturated fat intake and
reduction in CHD risk.
- -









Low trans fatty acid
vs. high trans fatty
acid intake
-
RR of coronary death = 1.39
(95% Cl 1.09–1.78) (p = 0.004)
for the highest vs. lowest
quintile of trans fatty
acid intake.
- -











PUFA intake was inversely
associated with CHD risk
(multivariate relative risk
(RR) for the highest vs. the
lowest quintile = 0.75, 95%
CI: 0.60–0.92;
p trend = 0.004), whereas
trans fat intake was
associated with an elevated
risk of CHD (RR = 1.33,
95% CI: 1.07, −1.66;
p trend = 0.01).
- -





adults free of CHD
High saturated fatty





47–59 years in the highest
quartile of intake of total fat,
saturated fatty acids, or
MUFA had higher CHD
mortality than did those in




























There was no association
between the risk of CHD















The overall pooled risk
reduction was 19% (RR =
0.81, 95% CI 0.70–0.95, p =
0.008), corresponding to 10%
reduced CHD risk (RR =
0.90, 95% CI = 0.83–0.97) for
each 5% energy of increased
PUFA.
- -










fat reduced the CVD
mortality (RR 0.95; 95% CI
0.80 to 1.12).
Lowering dietary saturated
fat reduced the CHD risk by
17% (risk ratio (RR) 0.83; 95%
confidence interval (CI) 0.72
to 0.96).
- -











LFD vs. HFD -
Total fat reduction replaced
with increased carbohydrate
and some protein, especially
plant-based protein, was
related to lower CHD risk
(in the upper quartile of
plant protein intake having a
CHD HR of 0.39 (95% CI:
0.22, 0.71), compared with
0.92 (95% CI: 0.57, 1.48) for
those in the lower quartile).
- -
Abbreviations: CHD—Coronary heart disease; CVD—cardiovascular disease; HFD—high-fat diet; LFD—low-fat diet; MUFA—Monounsaturated fatty acids; T2DM—type 2 diabetes mellitus; PUFA—
polyunsaturated fatty acids; RCT—randomized controlled trials; US—United States of America.
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6. Low-Carbohydrate Diet in Obesity
Carbohydrate restriction causes an increase in glycogenolysis, gluconeogenesis, and
fat oxidation to maintain proper blood glucose concentration [102,103]. One hypothesis as
to why LCD is effective in weight loss is that the aforementioned processes require more
energy expenditure; however, this hypothesis requires further confirmation [104,105]. Car-
bohydrate limitations, e.g., to 50 g per day, cause ketogenesis—an increased production of
ketone bodies, such as acetoacetate, β-hydroxybutyric acid, and acetone—as an alternative
source of energy [106]. Ketogenesis suppresses the appetite, which is one of the ways in
which weight can be lost on a ketogenic diet [104,107].
In their meta-analysis, Gibson et al. found that people on ketogenic diets were less
hungry and had a reduced desire to eat. The ketogenic diet protected them from an increased
appetite, despite weight loss [107]. A higher consumption of protein may also have a
satiating effect, because of the elevated level of satiety hormones [108]. LCD results in a
reduction in circulating insulin concentration, which promotes the transfer of triacylglycerol
into free fatty acids and glycerol [109,110]. Free fatty acids and glycerol are used by muscles,
and this results in a reduction in fat tissue and weight loss [109,110]. Another theory as
to why the LCD is effective in weight loss is that using this diet causes a reduction in the
overall calorie intake in practical terms [111]. The regime of the LCD means that food
choices are limited, which may lead to weight loss [111].
The results of studies concerned with the effects of LCDs on body weight vary, but
mainly indicate positive results, especially in the short term, and demonstrate better effects
than other diets [112–120]; however, Foster et al., in their study, which lasted two years,
did not find any difference between the compared diets [121]. LCD and VLCD may be
advantageous in relation to appetite, triglyceride, and medication use in T2DM, with
no clear evidence as to the advantages in terms of cardiometabolic risk [122]. Moreover,
the ketogenic diet resulted in better long-term body weight management with greater
reductions in body weight than LFD [117]. Table 4 summarizes the results of these studies.
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Average Duration of Follow-Up Population Diet Type Compared
Findings
(Weight Loss/Hunger)




Obese adults with T2DM or metabolic
syndrome LCD vs. LFD
LCD caused significantly greater weight loss than
LFD: −5.8 ± 8.6 kg vs. −1.9 ± 4.2 kg; p = 0.002.




Obese adults with lipid disorders and no
serious medical condition LCD vs. LFD
LCD caused significantly greater weight loss
than LFD: −12.9% vs. −6.7%; p < 0.001.
Brehm et al. (2005) [114]
RCT
1/50
4 months Obese adult women LCD vs. LFD
LCD caused significantly greater weight loss than
LFD: 9.79 ± 0.71 kg vs. 6.14 ± 0.91 kg; p < 0.05;
and body fat loss: 6.20 ± 0.67 kg vs.
3.23 ± 0.67 kg; p < 0.05.
Foster et al. (2010) [121]
Randomized parallel-group trial.
1/307
2 years Obese adults LCD vs. LFD
There was no statistically significant difference in
weight loss.
Bueno et al. (2013) [117]
Meta-analysis, RCT
13/1415
At least 12 months
Overweight and obese adults with no
restrictions based on sex, race or
co-morbidities.
VLCKD vs. LFD VLCKD caused significantly greater weight lossthan LFD: −0.91 (95% CI: −1.65, −0.17) kg.






Overweight and obese adults without
co-morbidities
VLCKD measured in visual analogue
scales.
No comparison to other diets
VLCKD caused significant decrease in hunger by
5.5 mm (95% CI: −8.5, −2.5) and desire to eat
decreased significantly by 8.9 mm (95% CI:
−16.0, −1.8).
Sackner-Bernstein (2015) et al. [115]
Meta-analysis, RCT
17/1797
8 weeks to 24 months
Overweight and obese adults with and
without co-morbidities. LCD vs. LFD
LCD caused significantly greater weight loss
than LFD: (95% CI) −2.0 (−3.1, −0.9) kg.




Obese adults with or without
co-morbidities LCD vs. control diet
LCD was associated with significantly greater
weight loss: (95% CI) −0.7 (−1.07, −0.33) kg;
and significantly greater decrease in fat mass:
−0.77 (−1.55, −0.32) kg.
Abbreviations: BMI—body mass index; CI—confidence interval; LCD—low-carbohydrate diet; LFD—low-fat diet; RCT—randomized controlled trials; VLCKD—very low-carbohydrate ketogenic diet.
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7. Low-Carbohydrate Diet in Type 2 Diabetes Mellitus
The European Society of Cardiology (ESC), European Association for the Study of
Diabetes (EASD), and American Diabetes Association (ADA) recommendations [45] state
that there is no single ideal dietary distribution of calories among carbohydrates, fats, and
proteins for T2DM patients, emphasizing the role of maintaining normal body weight in
this condition [45,123].
The fundamental issue of the implementation of LCD in the lifestyles of T2DM pa-
tients is maintaining this type of diet, especially in individuals that are treated with insulin,
because of the potentially increased risk of ketosis and hypoglycemia. Before the miracu-
lous discovery of insulin in the 1920s, the restriction of carbohydrates appeared to be one
of the ways in which patients with T2DM could be kept in better condition [124]. LCD was
used by Joslin in 1893 and Allen in 1914 in patients suffering from T2DM with varying
results, but they did have therapeutic success in some cases [125–127]. The improvement
of T2DM control with a dietary approach is essential, and one of the possible therapeutic
agents seems to be an LCD.
There are many studies, meta-analyses, and systematic reviews regarding LCDs’ ef-
ficiency in T2DM patients [73,77,80,128–133]. A meta-analysis carried out by Turton et al.
concluded that LCD intervention for T2DM management is safe and effective [128], and
one prospective Japanese study showed that LCDs were associated with decreased risk of
T2DM in women [129]. A meta-analysis cited in the ECS/EASD guidelines from 2019 [123]
indicates that the glucose-lowering effect of low- and high-carbohydrate diets is similar af-
ter 1 year or more and there is no significant effect on the weight or LDL-C levels [134]. The
main benefit of LCDs seems to be better glycemic control in T2DM, especially their effect
in terms of lowering HbA1c [77,130–132]; however, this benefit seems to be short term,
and there is controversy that is related to the Japanese population. LCD has a positive
role in lowering the dosages of insulin and fasting blood glucose [80]. The ketogenic diet
also seems to substantially reduce the glycemic response that results from dietary carbohy-
drates, as well as improving the underlying insulin resistance [133]. Table 5 summarizes
these studies.
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Population Diet Type Compared
Findings
T2DM Risk Incidence T2DM Control




Overweight and obese adults
with T2DM LCD vs. HCD -
Reduction in the need for antidiabetic drugs:
−0.5 ± 0.5 on LCD vs. −0.2 ± 0.5 on HCD;
p ≤ 0.03;
reduction in HbA1c: −2.6 ± 1.0%
(−28.4 ± 10.9 mmol/mol) on LCD vs.
−1.9 ± 1.2% (−20.8 ± 13.1 mmol/mol) on





Japanese adults without previous
history of T2DM LCD vs. other diets
LCD caused decreased risk of
T2DM incidence in women
(p < 0.001).
-




12 weeks to 4 years Adults with T2DM LCD vs. other diets -
LCD caused significantly greater reduction in
HbA1c than other diets: (95% CI)
−0.28 (−0.53, −0.02)% (p = 0.03).




1 year Adults with T2DM LCD vs. HCD -
LCD caused significantly greater reduction in
HbA1c than HCD: 0.34% (3.7 mmol/mol)
compared to HCD: (95% CI) 0.06%
(0.7 mmol/mol), 0.63% (6.9 mmol/mol).




3 months to 4 years Adults with T2DM
LCD vs
VLCD -
LCD had no effect on HbA1c: (95% CI) −0.09
(−0.27, 0.08)% (p = 0.30).
VLCD lead to significant HbA1c reduction:
(95% CI) −0.49 (−0.75, −0.23)% (p < 0.001).
Yamada et al. (2018) [132]
Systematic review
3/105
6 months Japanese T2DM adults
LCD vs. calorie-restricted
diet -
LCD caused significantly greater reduction in
HbA1c than calorie-restricted diet: 7.0 ± 0.7%
vs. 7.5 ± 1.0%; p = 0.03.








14 days to 24 months Adults with T2DM
LCD and VLCD,
No comparison to other diets -
All but one of the 41 included LCD
interventions were classified as effective in
T2DM and none was found to be unsafe.
Abbreviations: CI—confidence interval; HbA1c—glycated hemoglobin; HCD—high-carbohydrate diet; LCD—low-carbohydrate diet; RCT—randomized control trials; T2DM—type 2 diabetes mellitus; VLCD —
very low-carbohydrate diet.
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8. Low-Carbohydrate Diet and Cardiovascular Risk
There is controversy regarding restrictions related to carbohydrates, as attempts to
prevent cardiovascular risk began in the middle of the 21st century and, since that time, nu-
merous studies have been performed with mixed results, which means that the role of LCD
in patients with T2DM is unclear (EASD), as mentioned above [135–140]. After 20 years of
follow up, Halton et al. observed that diets lower in carbohydrates and higher in protein
and fat were not associated with an increased risk of CHD in women and, when the source
of the protein or fat was vegetables, the risk of CHD was moderately reduced [135]. One
prospective cohort study indicated that LCD was associated with an increased risk of atrial
fibrillation, regardless of the type of protein or fat used to replace the carbohydrates [136].
High- and low-carbohydrate diets were both associated with an increased mortality, with
minimal risk being observed at the daily carbohydrate intake of about 50–55% [137]. LCDs
with mainly animal-derived protein and fat sources were associated with higher mortality,
but LCDs consisting of plant-derived protein and fat sources were associated with lower
mortality [137]. LCDs were associated with a significantly higher risk of all-cause mor-
tality and they were not significantly associated with a risk of cardiovascular mortality
and incidence [138]. Low-carbohydrate, high-protein diets, without consideration of the
source of protein, were also associated with increased cardiovascular risk in Swedish
women [140]. An interesting perspective is the impact of LCDs on cardiovascular risk
factors, such as dyslipidemia, hypertension, obesity, postprandial hypoglycemia, and en-
dothelial dysfunction [111,112,117,118,141,142]. A randomized trial comparing VLCD and
calorie-restricted LFD in women with obesity indicated that VLCD was more efficient in
short-term weight loss [111]. The mean levels of blood pressure, lipids, fasting blood glu-
cose, and insulin were within the normal ranges in both groups [111]. LCD was associated
with a significantly lower predicted risk of atherosclerotic cardiovascular disease events
than LFDs in overweight and obese adults [112]. VLCD decreased body weight, triglyceride
concentration, and diastolic blood pressure, while increasing the concentration of HDL-C
and LDL-C [117]. A systematic review demonstrated that LCDs were more effective at six
months than LFDs in reducing the weight and cardiovascular disease risk [118]. Another
study proved that, in young adults of normal weight on LCDs for three weeks, LDL-C
increased by 44% vs. the control group [141]. Only one week of an LCD leads to a relative
impairment in glucose homeostasis in healthy young adults [142]. The authors stated that
this process may predispose the endothelium to hyperglycemia-induced damage, but there
is a need for further studies on young, healthy men [142]. The most recent meta-analysis
that is related to the effects of LCD on CVD risk factors confirmed that this type of diet
has a beneficial effect on cardiovascular risk, but long-term studies are needed in order to
confirm this [143]. As we know, T2DM is an important cardiovascular risk factor itself and
studies including T2DM patients also analyzed the other cardiovascular risk factors that are
mentioned above [144–147]. LCD intervention in patients with T2DM had a positive effect
on reducing triglyceride concentration and increasing HDL-C concentrations, without a
significant effect on long-term weight loss [144]. Another study indicated that an LCD
approach in patients with T2DM for an average of two years caused a significant reduction
in blood pressure, weight, and an improvement in lipid profiles [146]. Table 6 summarizes
the results of the studies related to LCD and CVD risk.
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Population Diet Type Compared
Findings
CVD Mortality CHD Risk Lipids/Blood Pressure AF





nurses from United States LCD vs. HCD -
LCD relative risk (95% CI)
for CHD: 0.94 (0.76–1.18,
p = 0.19).
- -






sample of Swedish adult
women
LCD vs. HCD -








At least 1 year
Adults with or without
comorbidities LCD vs. HCD
LCD risk ratio (95% CI) for
all-cause mortality: 1.31
(1.07–1.59)










Adults from United States
who did not report
extreme caloric intake
LCD vs. HCD
Mortality risk (95% CI) for
LCD: 1.2 (1.09–1.32).
Mortality risk (95% CI) for
HCD: 1.23 (1.11–1.36).
- - -
Zhang et al. (2019) [136]
Prospective, cohort
1/13 385
22.4 years Adults from United States LCD vs. HCD - - -
Increased risk of AF
incident (95% CI) for LCD:
HR = 0.82 (0.72-0.94) for
AF occurrence related to a
9.4% increase in
carbohydrate intake.




at least 3 months
Healthy adults from the
USA, Australia, UK, Israel
and China.






Decrease in systolic blood
pressure: −1.41 mmHg
(95% CI: —2.26, −0.56);
Decrease in diastolic blood
pressure: −1.71 mmHg
(95% CI: —2.36, −1.06);
Increase in plasma HDL-C:
0.1 mmol/L (95% CI: 0.08,
0.12);
Decrease in serum total
cholesterol: 0.13 mmol/L
(95% CI: 0.08, 0.19).
-
Abbreviations: AF—atrial fibrillation; CHD—coronary heart disease; CVD—cardiovascular disease; CI—confidence interval; HCD—high-carbohydrate diet; HDL-C—high-density lipoprotein cholesterol; HR –
hazard ratio; LCD—low-carbohydrate diet; RCT—randomized controlled trials.
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9. Fat and Sugar—New Insights
The debate regarding which single nutrient is the most important for reducing in
cardiometabolic risk is still ongoing, because, to date, the results of studies on this topic
have many limitations. Unlike previous studies [138,148], one prospective population-
based study [149] investigated the associations of not only macronutrients, but also their
components, with all-cause mortality and CVD. In that study, by the UK Biobank, there
were 502,536 participants recruited (aged 37–73 years) in 2007–2010, of whom 211,023
completed at least one dietary questionnaire and 195,658 were eligible for the study. There
was a mean follow-up period for a mortality of 10.6 years. The main finding was that
carbohydrates (sugar, starch, fiber) and proteins were non-linearly associated with all-cause
mortality. Similarly, a non-linear association was found for fiber, PUFA, and protein with
incidences of CVD. On the other hand, a linear association was observed between the
intake of SFA, MUFA, and PUFA for all-cause mortality and for total carbohydrate and
total fat with incident CVD. There was a lower risk of all-cause mortality and incident CVD
among patients whose current intake of starch, MUFA, and protein was low and had sugar
replaced with starch, MUFA, or protein. Moreover, replacing SFA with MUFA or protein
lowered the risk of the total mortality and CVD incidence. An important observation
coming from this study is that a divergent association of sugar and starch with all-cause
mortality can be found, and one should look not only at the amount, but also at the
components of carbohydrates. However, it must be also emphasized that the current intake
of a macronutrient should be considered, since the all-cause mortality was lowered only
among those patients who had sugar replaced with starch at the time when their current
intake of starch was low. As such, it cannot be generalized that replacing sugar with starch
in patients consuming higher amounts of starch will derive the same result. There are
also studies analyzing not only carbohydrate compounds, but also carbohydrate quality,
such as glycemic index (GI) or glycemic load (GL), which rank carbohydrates according to
the ability to increase blood glucose concentration. The results from a recently published
pan-European cohort study indicate that high GL or GI diets, which lead to a high glucose
response, are associated with higher CVD risk [150]. In addition to the amount and quality
of macronutrients, their production practices may also influence CVD, which has been
recently proven in a population-based cohort study [151]. In this study, a large amount
of ultra-processed foods in the diet was associated with higher risks of cardiovascular,
coronary heart, and cerebrovascular diseases [151].
10. Low-Fat, Low-Carbohydrate Diets in Relation to Microbiota in Cardiometabolic Risk
In recent years, it has become apparent that there is a relationship between diet, gut
microbiota, and metabolic health, including obesity and cardiovascular diseases. The gut
microbiota composition differs between obese and lean subjects; for instance, in obese
subjects, the Firmicutes to Bacteroides ratio is elevated, and a higher proportion of Acti-
nobacteria as well as reduced bacterial diversity is observed [152]. In relation to T2DM, a
lower abundance of fiber-degrading bacteria has been found [153], as well as a reduction in
Firmicutes phyla and an increase in Bacteroides to Firmicutes and Bacteroides to Pravotella
ratios [154]. Both of the dietary approaches, namely LFD or LCD, may (but also may not)
lead to weight loss, and there is substantial variability in the results in this regard. One ex-
planation for this may be the difference in gut microbiota. Food intake can be reduced due
to the influence of gut hormones that are stimulated by products of microbial fermentation,
such as butyrate and propionate [155]. Dietary adherence has become a major limitation
for sustained weight loss, which leads to a reduction in CVD risk [156].
One recent focus has been on the gut microbiota’s involvement in sustained weight
loss potential. Grembi et al., examining a cohort of obese adults enrolled in the DIETFITS
trial, proved that structured differences in gut microbiota may explain a portion of the
variability in weight loss success [157]. In that study, when determining whether gut
microbiota could predispose participants to successful 12-month weight loss following
LCDs or LFDs, the authors concluded that long-term weight loss is correlated with gut
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microbiota variability in a diet-dependent manner. Patients who were on LFDs and had
higher pre-diet microbiota plasticity had more sustained weight loss, whereas patients
who were on an LCD and had higher microbiota variability over 10 weeks of dietary
treatment had increased 12-month weight loss. To the best of our knowledge, there is only
one study that directly relates the effect of dietary fat on gut microbiota and addresses
their relationship with cardiometabolic diseases. In this study, Wan et al. [158] showed that
higher fat consumption was associated with unfavorable changes in the gut microbiota, as
well as fecal metabolomics and plasma proinflammatory factors.
High-fat and high-sugar Western diets negatively impact on human metabolic health
through alterations in the gut microbiota. Microbiota-accessible carbohydrates, which are
found in dietary fiber, shaping the microbial ecosystem, are reduced in Western diets [159].
In addition, the microbiota can affect cholesterol balance and, through this mechanism,
CHD development [160]. The first studies that proved the potential link between the gut
microbiome and CVD analyzed trimethylamine N-oxide (TMAO), which is a metabolite
arising from the ingestion of dietary nutrients that are abundant in a Western diet, namely
lecithin, choline, and carnitine [161]. In turn, there is an association between TMAO
concentration and increased cardiovascular risk and mortality, as observed in large-scale
clinical cohorts [162].
It is also worth noting that food production practices and additives (e.g., emulsifiers
and non-caloric artificial sweeteners) influence human health, including the gut micro-
biota [163,164].
11. Conclusions
The question of which type of diet—LCD or LFD—is better for cardiometabolic health
remains unanswered. LCDs and LFDs can both be successful in relation to weight loss
(which, in turn, indirectly improves cardiovascular risk), but the differences may be de-
pendent on the host microbiome. Food production practices, fiber content, carbohydrate
sources, and fatty acid quality may play a significant role in cardiovascular risk manage-
ment. Identifying features of the gut microbiota that can predict adherence to the specific
diet type and may help to personalize dietary interventions will be necessary.
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